Showing 15 posts of 243 posts found.


MSD’s Keytruda boosts overall survival by 31% in advanced oesophageal cancer

January 16, 2019
Research and Development Cancer, MSD, keytruda, oesophageal cancer, pharma

MSD has unveiled new Phase 3 data for its blockbuster anti-PD-1 immunotherapy Keytruda (pembrolizumab), showing that the drug succeeded in …


MSD chalks up two HIV drug approvals in Europe

November 30, 2018
Medical Communications, Sales and Marketing Delstrigo, EU, Europe, HIV, MSD, Pifeltro, pharma

MSD has announced the European approval of two of its products for the treatment of HIV: the single-tablet combination Delstrigo …

MSD’s Keytruda to treat melanoma in England on the Cancer Drugs Fund

November 19, 2018
Sales and Marketing England, MSD, NHS, UK, keytruda, melanoma, pharma

MSD’s blockbuster immunotherapy Keytruda (pembrolizumab) will now be made available to patients in England via the Cancer Drugs Fund, it …


MSD’s Keytruda improvess overall survival in Phase 3 oesophageal cancer

November 15, 2018
Research and Development Cancer, MSD, PD-L1, keytruda, pharma

MSD has announced new Phase 3 data on its anti-PD-1 therapy Keytruda (pembrolizumab) as a second-line treatment for advanced or …


MSD’s Keytruda/chemo combo scores first-line FDA approval in NSC lung cancer

November 1, 2018
Sales and Marketing Cancer, MSD, NSCLC, keytruda, lung cancer, pharma

MSD’s blockbuster anti-PD-1 immunotherapy has secured another FDA approval, it has emerged, in combination with carboplatin and either paclitaxel or …


First-line Keytruda shows better overall survival in head & neck cancer

October 23, 2018
Manufacturing and Production, Research and Development Cancer, ESMO 2018, MSD, head and neck cancer, keytruda, pharma

MSD’s Keytruda (pembrolizumab) made an impact at the European Society for Medical Oncology 2018 Congress as the company unveiled new …


MSD’s Keytruda with Pfizer’s Inlyta beats Sutent in most common kidney cancer

October 19, 2018
Medical Communications, Research and Development Cancer, Kidney cancer, MSD, Pfizer, inlyta, keytruda, pharma

MSD has unveiled new Phase 3 data on its blockbuster anti-PD-1 cancer therapy Keytruda (pembrolizumab) as part of a combination, …


MSD and Samsung Bioepis terminate development of Lantus biosimilar for diabetes

October 15, 2018
Research and Development, Sales and Marketing Lantus, MSD, Samsung Bioepis, Sanofi, biosimilar, diabetes, pharma

MSD has reportedly terminated a previous agreement with Samsung Bioepis which would have seen them collaborate on a biosimilar version …


MSD signs $117m deal with Samsung Bioepis over Janssen biosimilar

October 8, 2018
Sales and Marketing Biogen, Janssen, MSD, Samsung, Samsung Bioepis

American multinational MSD have won a $117 million contract allowing them to supply Samsung Bioepis’ Renflexis to the US Department …

Memorial Sloan Kettering Chief resigns from MSD board

October 3, 2018
Research and Development MSD, Memorial Sloan Kettering Cancer Center, pharma

Dr Craig Thompson, Chief Executive of Memorial Sloan Kettering Cancer Center (MSKCC), the renowned non-profit treatment and research institution based …


Kenneth Frazier to continue as CEO as MSD rescinds mandatory retirement policy

September 27, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Kenneth Frazier, MSD, pharma

MSD has pitched a curveball with the news that the company has rescinded its policy mandating that Chief Executive Officers …


MSD to launch Keytruda at half US list price in China

September 20, 2018
Business Services, Sales and Marketing BMS, China, MSD, global, keytruda, markets, pricing

US pharma giant MSD will offer cutting edge cancer treatment Keytruda to Chinese patients at half the price at what …


Pfizer, Novartis, MSD, Novo and GSK halt operations in wake of Hurricane Florence

September 14, 2018
Medical Communications GSK, Hurricane Florence, MSD, Novartis, Novo Nordisk, Pfizer, pharma

As Hurricane Florence begins to breach the Southeast Coast, major pharma firms have announced they are enacting contingency plans, including …


Keytruda scores ground-breaking European approval in lung cancer subgroup

September 10, 2018
Sales and Marketing Cancer, EU, Europe, MSD, Merck, NSCLC, keytruda, lung cancer, pharma

Keytruda (pembrolizumab) has chalked up yet another approval for MSD, this time in Europe in combination with permextred and platinum-based …


MSD’s experimental vaccine to be used in fight against Congo Ebola outbreak

August 8, 2018
Research and Development Congo, Ebola, MSD, Merck, Vaccine, pharma

MSD’s experimental drug rVSV-ZEBOV will be used in tackling the latest Ebola outbreak in the Democratic Republic of Congo, after …

Latest content